A photo released by federal prosecutors shows a burnt-out letter “P” on the sign of Chans Pharmacy in Pembroke Pines, reading simply “HARMACY.” Perhaps it was a fitting label for a storefront with an ...

It’s been about five years since the U.S. Food and Drug Administration approved Wegovy for chronic weight management, but semaglutide, the active ingredient in Ozempic and similar drugs, goes back ...

The percentage of American adults who are currently taking a GLP-1 drug for weight loss is 11%, according to a new survey from Gallup. That’s up from 8% in 2025 and 3% in 2024, according to the ...

NEW YORK (AP) — Popular — and expensive — GLP-1 weight loss drugs just got a lot cheaper for many older Americans. Starting Wednesday, the federal government is offering a selection of the brand name ...

Popular GLP-1 weight-loss drugs are becoming much more affordable for millions of older adults starting Wednesday, July 1, as Medicare begins to cover them — for now. The Medicare GLP-1 Bridge is a ...

Some Medicare patients will be able to access to GLP-1 medication for weight loss for the first time starting July 1, paying a $50 monthly copay through a new program designed to make the drugs more ...

Experts are intrigued by the theory. Here’s what early research suggests. By Dana G. Smith See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de ...

SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer (PFE.N), opens new tab and Innovent Biologics (1801.HK), opens new tab have passed a preliminary review to be potentially included in China's ...

Share on Pinterest GLP-1 drugs can provide benefits that may boost an athlete’s performance, but do these medications give them the competitive edge? Getty Images/The Good Brigade Debates are emerging ...

One in eight Americans now use GLP-1 weight loss drugs like Ozempic and Wegovy. The rise of telehealth services has made it easier for patients to get these drugs, often without insurance. Health ...

A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to a 12% reduction in body weight after 36 weeks, according to a randomized phase II clinical ...